On January 28, 2026 InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, reported the extension of collaboration with BeOne Medicines, a global oncology company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this project mechanistic translational modeling will be applied to support selection of minimal recommended starting dose and step-up dosing regimen to mitigate cytokine release syndrome and optimize dose-escalation clinical study design.

"Nowadays, trimer-based mechanistic modeling has become an essential tool to guide the selection of an appropriate starting dose for first-in-human trials of T-cell engagers, ensuring the dose is high enough to be effective while avoiding sub-therapeutic levels and multiple dose escalation steps," said Oleg Demin Jr, Head of Oncology and Immuno-Oncology, InSysBio. "InSysBio’s generic QSP model for T-cell engagers mechanistically captures the difference between in vitro and clinical settings, supporting precise preclinical-to-clinical translation. Consequently, it allows prediction of not only the starting dose but also the step-up dosing regimen based on preclinical data."

(Press release, BeOne Medicines, JAN 28, 2026, View Source [SID1234662335])